Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Neuroscience Letters

• Publication date

  2012-04-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.neulet.2012.02.037PMID 22387067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects

  2012cited by this paper
• Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.

  2012cited by this paper
• Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial

  2011cited by this paper
• Intranasal insulin as a therapeutic option in the treatment of cognitive impairments.

  2011cited by this paper
• Therapeutic Efficacy of Intranasally Delivered Mesenchymal Stem Cells in a Rat Model of Parkinson Disease

  2011cited by this paper
• Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

  2010cited by this paper
• Efficient and targeted delivery of siRNA in vivo

  2010cited by this paper
• Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

  2009cited by this paper
• Intranasal delivery of cells to the brain.

  2009cited by this paper
• Potential application of RNAi for understanding and therapy of neurodegenerative diseases.

  2009cited by this paper
• Knocking down barriers: advances in siRNA delivery

  2009cited by this paper
• RNAi therapeutics: an update on delivery.

  2008cited by this paper
• New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163.

  2008cited by this paper
• Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy.

  2008cited by this paper
• Delivery of Galanin-Like Peptide to the Brain: Targeting with Intranasal Delivery and Cyclodextrins

  2008cited by this paper
• From nose to brain: understanding transport capacity and transport rate of drugs

  2008cited by this paper
• Intranasal insulin improves cognition and modulates β-amyloid in early AD

  2008cited by this paper
• Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease

  2008cited by this paper
• Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies

  2008cited by this paper
• Intranasal Insulin Administration Dose-Dependently Modulates Verbal Memory and Plasma Amyloid-β in Memory-Impaired Older Adults

  2008cited by this paper
• Intranasally delivered TGF-beta1 enters brain and regulates gene expressions of its receptors in rats.

  2007cited by this paper
• Targeting neurological disease with RNAi.

  2007cited by this paper
• Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype.

  2006cited by this paper
• Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs.

  2006cited by this paper
• Olfactory ensheathing cells and olfactory nerve fibroblasts maintain continuous open channels for regrowth of olfactory nerve fibres

  2005cited by this paper
• Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.

  2004cited by this paper
• Intranasal insulin improves memory in humans.

  2004cited by this paper
• Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis.

  2004cited by this paper
• Ensheathment of the olfactory nerves in the adult rat

  2003cited by this paper
• Visualization of In Vivo Olfactory Uptake and Transfer Using Fluorescein Dextran

  2002cited by this paper
• [Olfactory disorders in Alzheimer's disease and in Parkinson's disease. Review of the literature].

  2000cited by this paper
• Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway

  1998cited by this paper

• Engineered commensals for targeted nose-to-brain drug delivery.

  2025cites this paper
• Framework Nucleic Acid Nanomaterials for Central Nervous System Therapies: Design for Barrier Penetration, Targeted Delivery, Cellular Uptake, and Endosomal Escape.

  2025cites this paper
• Nose-to-brain drug delivery: from bench to bedside

  2025cites this paper
• Intranasal drug delivery Dynamics: Extracellular and intracellular pathways revealed by Fluoro-Gold tracer in a mouse model.

  2025cites this paper
• Uptake of Mesenchymal Stem Cell-Derived Exosomes in Mouse Brain through Intranasal Delivery

  2024cites this paper
• Nucleic acid-based therapeutics for the treatment of central nervous system disorders

  2023cites this paper
• Intranasal GHK peptide enhances resilience to cognitive decline in aging mice

  2023cites this paper
• Single therapeutic dose of an antiviral UL29 siRNA swarm diminishes symptoms and viral load of mice infected intranasally with HSV‐1

  2023cites this paper
• Nanocarriers for Delivery of Oligonucleotides to the CNS

  2022cites this paper
• Applications of direct nose-to-brain drug delivery in biomedicine, biotechnology, tissue engineering, and immunology

  2021cites this paper
• Self-assembling modified neuropeptide S enhances nose-to-brain penetration and exerts a prolonged anxiolytic-like effect.

  2021cites this paper
• Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles

  2021cites this paper
• Novel Formulations and Drug Delivery Systems to Administer Biological Solids.

  2021cites this paper
• Direct transport theory: From the nose to the brain

  2021cites this paper
• Intranasal Insulin: a Treatment Strategy for Addiction

  2020cites this paper
• The Use of Peptide and Protein Vectors to Cross the Blood-Brain Barrier for the Delivery of Therapeutic Concentration of Biologics

  2020cites this paper
• Particles Containing Cells as a Strategy to Promote Remyelination in Patients With Multiple Sclerosis

  2020cites this paper
• Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases.

  2019cites this paper
• Comparison of intranasal versus intravenous midazolam for management of status epilepticus in dogs: A multi‐center randomized parallel group clinical study

  2019cites this paper
• Gene Therapy for Cognitive Recovering After Ischemic Stroke

  2018cites this paper
• Mechanism of intranasal drug delivery directly to the brain

  2018influential citation
• Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy.

  2017cites this paper
• Intranasal insulin in Alzheimer’s disease: Food for thought

  2017cites this paper
• Terapia génica en enfermedades neurodegenerativas y demencia post infarto cerebral: perspectiva de traslación

  2017cites this paper
• Limiting the level of tertiary amines on polyamines leads to biocompatible nucleic acid vectors.

  2017cites this paper
• Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.

  2017cites this paper
• Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I

  2017cites this paper
• Relative vascular permeability and vascularity across different regions of the rat nasal mucosa: implications for nasal physiology and drug delivery

  2016influential citation
• Improving drug delivery technology for treating neurodegenerative diseases

  2016cites this paper
• Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial

  2016cites this paper
• Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles

  2015cites this paper
• Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration

  2015cites this paper
• Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.

  2015cites this paper
• Transport Mechanisms of Neurotherapeutics across the Blood-Brain Barrier eBooks

  2015cites this paper
• Interrogating the role of splicing factors in Huntington’s Disease

  2015cites this paper
• The dysregulation of microRNAs due to mutant p53R172H expression in a mouse model of pancreatic ductal adenocarcinoma

  2015cites this paper
• Social Hormones and Human Behavior: What Do We Know and Where Do We Go from Here

  2015cites this paper
• Advances in Neurotherapeutic Delivery Technologies

  2015cites this paper
• Intranasal delivery for peptide and siRNA to the brain using lipid-based nanocarriers for the treatment of neuroinflammation

  2014influential citation
• Intranasal Drug Delivery to the Brain

  2014cites this paper
• Evaluation of the safety and brain-related tissues distribution characteristics of TAT-HaFGF via intranasal administration.

  2014cites this paper
• Exon-Skipping Antisense Oligonucleotides to Correct Missplicing in Neurogenetic Diseases

  2014cites this paper
• Intranasal exposure to uranium results in direct transfer to the brain along olfactory nerve bundles

  2014cites this paper
• Intranasal therapeutic strategies for management of Alzheimer’s disease

  2014cites this paper
• Agile delivery of protein therapeutics to CNS.

  2014cites this paper
• Improving brain drug targeting through exploitation of the nose-to-brain route: a physiological and pharmacokinetic perspective.

  2014cites this paper
• Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain

  2014cites this paper
• siRNA Treatment: “A Sword-in-the-Stone” for Acute Brain Injuries

  2013cites this paper
• Short interfering RNA and the central nervous system: development of nonviral delivery systems

  2013cites this paper
• Full Length Article

  2013cites this paper
• A comparative evaluation of the regulation of GM crops or products containing dsRNA and suggested improvements to risk assessments.

  2013cites this paper
• Nanotechnology for CNS delivery of bio-therapeutic agents

  2013cites this paper
• Novel siRNA delivery strategy: a new “strand” in CNS translational medicine?

  2013cites this paper
• Intranasal Delivery of pGDNF Nanoparticles for Parkinson's Disease

  2013cites this paper
• Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles

  2013cites this paper
• Intranasal administration of oxytocin: Behavioral and clinical effects, a review

  2013cites this paper
• Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders

  2013cites this paper
• Small RNA drugs for prion disease: a new frontier

  2013cites this paper
• [Characteristics of olfactory epithelium and manipulations of neural functions in the brain by the intranasal administration].

  2012cites this paper
• Therapeutic Efficacy of Intranasally Delivered Mesenchymal Stem Cells in a Rat Model of Parkinson Disease

  2011cites this paper